Glioblastoma multiforme: Pathogenesis and treatment
作者： Constantinos Alifieris , Dimitrios T. Trafalis
DOI: 10.1016/J.PHARMTHERA.2015.05.005
关键词: Glioblastoma 、 Targeted therapy 、 Internal medicine 、 Radiation therapy 、 Pathogenesis 、 Oncology 、 Medicine 、 Bioinformatics 、 Disease 、 Stem cell 、 Chemotherapy 、 Glioma
摘要: … median survival is short: only about 15 months. A deeper understanding of the pathogenesis … we review the current concepts as well as emerging advances in the treatment of GBM with …
elsevier.com
sci-hub.se 参考文章(297)
John D Hainsworth, Gregg C Shepard, David R Spigel, Kent C Shih, Brett T Brinker, Guy W Tillinghast, Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clinical advances in hematology & oncology. ,vol. 10, pp. 240- 246 ,(2012)
Marie-Thérése Stockhausen, Karina Kristoffersen, Hans Skovgaard Poulsen, Notch signaling and brain tumors. Advances in Experimental Medicine and Biology. ,vol. 727, pp. 289- 304 ,(2012) , 10.1007/978-1-4614-0899-4_22
Mengxian Zhang, Tobias W. Herion, Carmen Timke, Na Han, Kai Hauser, Klaus J. Weber, Peter Peschke, Ute Wirkner, Michael Lahn, Peter E. Huber, Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia. ,vol. 13, pp. 537- 549 ,(2011) , 10.1593/NEO.11258
Jean Khoury, El Rassi, Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia Pharmacogenomics and Personalized Medicine. ,vol. 6, pp. 57- 62 ,(2013) , 10.2147/PGPM.S32145
Yang Wang, Li Pan, Xiao-fang Sheng, Shu Chen, Jia-zhong Dai, Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia-pacific Journal of Clinical Oncology. ,vol. 12, pp. 23- 29 ,(2016) , 10.1111/AJCO.12166
Shlomit Yust-Katz, Diane Liu, Ying Yuan, Vivien Liu, Sanghee Kang, Morris Groves, Vinay Puduvalli, Victor Levin, Charles Conrad, Howard Colman, Sigmonid Hsu, W. K. Alfred Yung, Mark R. Gilbert, Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. ,vol. 119, pp. 2747- 2753 ,(2013) , 10.1002/CNCR.28031
Phyllis Langone, Priya Ranjan Debata, Joseph Del Rosario Inigo, Sukanta Dolai, Sumit Mukherjee, Peter Halat, Kristina Mastroianni, Gina Marie Curcio, Mario R. Castellanos, Krishnaswami Raja, Probal Banerjee, Coupling to a glioblastoma-directed antibody potentiates antitumor activity of curcumin International Journal of Cancer. ,vol. 135, pp. 710- 719 ,(2014) , 10.1002/IJC.28555
J. Ransohoff, C. B. Wilson, M. D. Walker, S. B. Green, D. P. Byar, J. T. Robertson, J. Mealey, W. R. Shapiro, R. G. Selker, T. A. Strike, W. H. Brooks, K. R. Smith, P. Paoletti, U. Batzdorf, G. L. Odom, D. A. Pistenmaa, W. E. Hunt, E. Alexander, Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer treatment reports. ,vol. 67, pp. 121- 132 ,(1983)
Björn Silkenstedt, Ioanna Alexandros Rota, Eleni Adamopoulou, Ulrike Naumann, Oliver Podlech, Elisabeth Höring, The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells. Anticancer Research. ,vol. 33, pp. 1351- 1360 ,(2013)
Oliver-Louis Chinot, Stephane Honore, Henry Dufour, Maryline Barrie, Dominique Figarella-Branger, Xavier Muracciole, Diane Braguer, Pierre-Marie Martin, François Grisoli, None, Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy Journal of Clinical Oncology. ,vol. 19, pp. 2449- 2455 ,(2001) , 10.1200/JCO.2001.19.9.2449